No definition available.
Malignant neoplasm of vagina, excluding all cancers (controls excluding all cancers)
C3_VAGINA_EXALLC
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleonly females |
293373 |
2. Check conditionsNone |
293373 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
106 |
4. Check minimum number of eventsNone |
106 |
5. Include endpointsNone |
106 |
6. Filter based on genotype QC (FinnGen only) |
106 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of vagina, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- malignant neoplasm of female genital organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
- Neoplasms
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 106 | 106 | - |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | - |
| Median age at first event (years) | 63.13 | 63.13 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 50
- Matched controls
- 499
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8070/3-C52.9
ICD-O-3
Squamous cell carcinoma, NOS, of vagina, NOS
+∞
35.7
30
*
C52.91
ICD-10 Finland
Squamous cell carcinoma of the vagina
+∞
34.3
29
*
LEB00
NOMESCO Finland
Biopsy of vagina
329.7
31.7
29
*
128
Kela drug reimbursment
Cancers of female genital organs
+∞
31.6
27
*
A03FA01
ATC
metoclopramide; systemic, rectal
20.2
18.8
32
40
H02AB02
ATC
dexamethasone; systemic
74.0
17.5
19
*
WF002
NOMESCO Finland
Radical radiotherapy
+∞
16.5
15
*
C52.90
ICD-10 Finland
Malignant neoplasm of vagina without histologic examination
+∞
15.4
14
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
15.4
14
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
14.2
13
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
14.2
13
*
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
+∞
14.2
13
*
ULA02
NOMESCO Finland
Kolposcopy
15.3
13.2
23
26
C52
ICD-10 Finland
Malignant neoplasm of vagina
+∞
13.1
12
*
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
153.8
12.0
12
*
C52.99
ICD-10 Finland
Malignant tumor of the vagina, unspecified histology
+∞
11.9
11
*
L03AA13
ATC
pegfilgrastim; parenteral
+∞
11.9
11
*
JN4BD
NOMESCO Finland
Extensive body CT
17.2
11.8
19
17
UKC02
NOMESCO Finland
Cystoscopy
12.5
11.1
21
27
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
10.8
10
*
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
+∞
10.8
10
*
ZX040
NOMESCO Finland
Intracavity HDR radiotherapy
+∞
10.8
10
*
A04AA01
ATC
ondansetron; systemic, rectal
23.0
10.7
15
9
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
7.8
10.5
34
106
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
34.1
10.4
13
5
XX3DW
NOMESCO Finland
Time consuming IT work
20.7
10.3
15
10
A04AA02
ATC
granisetron; systemic, transdermal
+∞
9.7
9
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
9.7
9
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
9.7
9
*
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
8.7
9.3
22
41
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
34.3
8.9
11
*
JN4AD
NOMESCO Finland
Body CT examination
34.3
8.9
11
*
A04AD12
ATC
aprepitant; systemic
+∞
8.6
8
*
LEC00
NOMESCO Finland
Partial excision of vagina
+∞
8.6
8
*
WW500
NOMESCO Finland
Blood transfusion
40.6
8.4
10
*
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
15.4
8.1
13
11
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
8.7
8.0
18
30
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
7.5
7
*
ZX095
NOMESCO Finland
Combined chemoradiotherapy
+∞
7.5
7
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
7.5
7
*
C52.92
ICD-10 Finland
Adenocarcinoma of the vagina
+∞
7.5
7
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
7.5
7
*
N02AA05
ATC
oxycodone; systemic
8.0
7.3
17
30
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
5.3
7.1
28
97
LEB10
NOMESCO Finland
Excision of lesion of vagina
46.4
7.0
8
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
31.0
6.4
8
*
F43.29
ICD-10 Finland
Adaptation disorder UNS
31.0
6.4
8
*
X77
ICPC
Malignant neopl genital female other
+∞
6.4
6
*
130
Kela drug reimbursment
Malignant tumour
+∞
6.4
6
*
WC105
NOMESCO Finland
Simple cytostatic therapy of local tumor recidive
+∞
6.4
6
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
6.4
6
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
6.4
6
*
D39.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other female genital organs
+∞
6.4
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
23
44
6.40
12.17
3.9
1.4
5.0
3.0
ug/l
0.66
16
34
16
35
5.21
7.20
1.6
1.5
—
—
—
0
0
66
373
3.04
7.13
6.8
3.6
—
—
—
0
0
43
195
3.03
6.87
2.3
1.4
—
—
—
0
0
57
304
2.89
6.74
4.9
3.1
—
—
—
0
0
10
21
5.15
4.63
1.3
1.2
—
—
—
0
0
27
116
2.78
4.56
10.8
7.1
—
—
—
0
0
42
231
2.36
4.22
4.3
3.1
0.5
0.6
e6/l
0.35
36
164
34
171
2.46
4.16
4.7
2.0
—
—
—
0
0
10
24
4.50
3.98
1.2
1.2
116.4
70.8
pmol/l
—
10
24
41
233
2.24
3.75
6.4
4.2
0.0
0.0
estimate
—
10
74
26
121
2.52
3.71
2.5
1.8
—
—
—
0
0
7
11
6.72
3.24
1.6
1.2
—
—
—
0
0
20
88
2.57
3.17
2.4
1.8
—
—
—
0
0
7
12
6.16
3.07
1.6
1.2
—
—
—
0
0
66
475
2.03
3.07
6.4
5.5
0.0
0.0
estimate
—
8
70
20
90
2.51
3.03
2.3
1.8
—
—
—
0
0
8
17
5.00
2.98
2.1
1.4
—
—
—
0
0
15
59
2.80
2.93
2.5
1.3
—
—
—
0
0
66
480
1.99
2.92
5.5
3.9
0.0
0.0
estimate
0.00
11
72
18
83
2.41
2.59
9.4
3.0
5.2
5.8
kpa
2.11
18
83
5
7
7.42
2.57
2.4
1.4
—
—
—
0
0
5
8
6.49
2.40
1.8
1.3
—
—
—
0
0
63
471
1.83
2.36
5.5
3.9
0.0
0.0
estimate
0.00
11
75
61
452
1.82
2.35
9.0
4.9
1.2
1.2
mmol/l
2.20
54
401
20
101
2.21
2.34
4.4
2.5
21.3
22.9
%
0.16
13
90
7
18
4.09
2.29
2.7
1.5
—
—
—
0
0
83
934
0.49
2.20
5.1
5.4
2.9
2.8
mmol/l
0.50
78
861
6
14
4.47
2.18
1.2
1.2
—
—
—
0
0
77
884
0.53
2.08
6.4
5.9
40.6
39.9
mmol/mol
0.26
70
818
82
923
0.51
2.05
5.4
4.8
6.0
6.0
mmol/l
0.27
76
841
17
87
2.14
1.93
10.5
3.4
1.0
1.0
mmol/l
0.15
17
73
10
41
2.59
1.81
1.8
1.7
—
—
—
0
0
7
25
2.92
1.68
1.6
2.3
—
—
—
0
0
13
63
2.21
1.68
1.8
1.7
44.0
57.9
ml/min/173m2
—
5
23
25
155
1.80
1.66
4.2
2.6
1.1
1.2
e6/l
0.07
14
83
48
360
1.61
1.58
3.8
3.8
83.7
23.2
ng/l
0.46
37
254
11
51
2.29
1.56
4.9
2.1
24.5
25.4
mmol/l
0.62
11
51
5
16
3.23
1.45
1.4
1.1
—
—
—
0
0
32
222
1.63
1.42
2.6
2.0
3.0
3.6
mg/l
0.68
27
183
9
42
2.25
1.37
6.1
5.9
1.5
1.5
%
—
9
42
5
17
3.03
1.37
1.8
1.4
—
—
—
0
0
5
17
3.03
1.37
1.8
1.4
—
—
—
0
0
47
361
1.54
1.35
6.2
3.9
—
—
—
0
0
0
33
0.00
1.18
0.0
1.9
—
—
—
0
0
9
157
0.53
1.09
1.0
1.5
—
—
—
0
0
9
48
1.95
1.03
2.3
1.4
—
—
—
0
0
9
51
1.83
0.97
3.1
3.5
4.8
5.3
kpa
—
9
45
21
145
1.56
0.94
4.5
2.9
0.6
4.3
e6/l
—
10
75
12
187
0.60
0.89
1.2
1.3
26.6
43.0
iu/ml
—
5
70
8
47
1.76
0.83
5.4
2.1
1.1
1.2
%
—
8
47
12
183
0.61
0.81
1.2
1.3
3.3
10.6
u/ml
—
7
63
0
25
0.00
0.80
0.0
1.1
—
—
—
0
0
13
84
1.62
0.76
2.3
3.7
449.2
175.8
ng/l
0.44
13
77
12
79
1.59
0.66
2.9
3.5
—
—
—
0
0
5
29
1.76
0.64
2.8
1.7
—
—
—
0
0
5
29
1.76
0.64
1.2
1.6
—
—
—
0
0
26
204
1.36
0.62
1.7
1.8
1.3
1.0
mg/l
0.31
20
162
7
47
1.52
0.48
6.1
2.5
51.9
44.0
%
—
7
47
63
684
0.81
0.46
3.5
4.5
16.2
12.9
mm/h
0.85
57
627
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
21.7
—
0
15
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
94
969
0.74
0.35
18.5
8.9
23.0
22.7
u/l
0.09
94
925
6
45
1.35
0.34
1.2
1.0
—
—
—
0
0
47
512
0.85
0.30
2.8
2.8
—
—
—
0
0
93
902
1.25
0.26
28.3
12.0
29.7
20.0
mg/l
2.17
85
658
5
37
1.37
0.24
1.4
1.2
—
—
—
0
0
5
37
1.37
0.24
1.4
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
4.0
—
0
6
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
19
215
0.86
0.19
1.2
1.3
0.8
2.7
u/ml
—
8
51
93
949
0.84
0.16
31.4
14.5
138.8
139.9
mmol/l
2.68
93
920
93
949
0.84
0.16
31.4
14.6
4.0
4.0
mmol/l
0.19
93
919
39
414
0.91
0.14
1.9
2.1
94.2
103.1
pmol/l
0.32
19
183
5
48
1.04
0.09
1.6
1.6
—
—
—
0
0
5
48
1.04
0.09
20.8
4.0
26.0
25.4
mmol/l
—
5
48
94
953
0.88
0.09
33.0
14.0
79.2
70.5
umol/l
0.73
94
953
40
383
1.07
0.08
4.3
2.7
175.1
82.7
ug/l
1.25
33
347
29
278
1.06
0.05
2.4
2.9
1565.8
1554.3
ng/l
0.00
24
235
85
847
1.02
0.00
22.5
10.9
73.9
76.1
ml/min/173m2
0.36
76
664
5
53
0.94
0.00
1.6
1.6
—
—
—
0
0
5
57
0.87
0.00
1.6
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
5
49
1.02
0.00
3.4
3.3
5.4
4.5
pmol/l
—
5
43
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_VAGINA_EXALLC – Malignant neoplasm of vagina, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).